CorMedix (CRMD) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed CorMedix (CRMD) over the past year, gaining 91.1% versus a loss of 34.4%. Over five years, CRMD leads with a +47.1% price change compared with -55.0% for SLN. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($586.7 million vs $570.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | SLN |
|---|---|---|
| Share price | $7.33 | $9.44 |
| Market cap | $570.94M | $586.73M |
| 1-day change | +0.62% | -3.87% |
| YTD return | -37.40% | +61.51% |
| 1-year return | -34.36% | +91.05% |
| 5-year return | +47.07% | -55.00% |
| P/E ratio (TTM) | 3.57 | — |
| Forward P/E | 20.93 | — |
| EPS (TTM) | $2.05 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $17.58 |
| 52-week low | $6.13 | $4.19 |
| Distance from 52-week high | -43.74% | -46.29% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +109.28% | +249.58% |
| Average volume | 1.06M | 1.12M |
| Shares outstanding | 77.94M | 62.15M |
| Employees | 191 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed CRMD by 125.4 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
CRMD vs SLN FAQ
Which is bigger, CorMedix or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $586.73M compared with $570.94M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or SLN?
SLN returned +91.05% over the past 12 months, compared with -34.36% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.